Is intravenous pulse administration of cyclophosphamide an effective and safe treatment for sensitized cardiac allograft recipients?
Immunosuppression incorporating intravenous cyclophosphamide before and after transplantation is safe and highly effective in sensitized cardiac transplant recipients. When used after transplantation as part of triple immunosuppression, cyclophosphamide is superior to mycophenolate mofetil in reducing rejection. The mechanism may involve prevention of diversification of the recipient immune response to donor HLA class II molecules.
In conclusion, geraniol ameliorates impaired vascular reactivity in experimentally induced diabetes and MS. The effect may be partially attributed to an endothelium-independent pathway involving blockage of both voltage dependent and receptor operated calcium channel.